denkapparat Operations GmbH Invests $313,000 in ResMed Inc. (NYSE:RMD)

denkapparat Operations GmbH acquired a new position in ResMed Inc. (NYSE:RMD - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,368 shares of the medical equipment provider's stock, valued at approximately $313,000.

Several other large investors have also made changes to their positions in RMD. Howard Capital Management Inc. increased its position in ResMed by 5.3% in the 4th quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider's stock worth $206,000 after buying an additional 45 shares during the period. Ascent Group LLC lifted its stake in shares of ResMed by 1.7% in the third quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider's stock valued at $714,000 after buying an additional 48 shares during the period. SkyView Investment Advisors LLC lifted its position in shares of ResMed by 2.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider's stock worth $637,000 after acquiring an additional 51 shares during the period. Wedmont Private Capital increased its holdings in ResMed by 2.6% in the 4th quarter. Wedmont Private Capital now owns 2,032 shares of the medical equipment provider's stock valued at $475,000 after buying an additional 52 shares during the period. Finally, Brooklyn Investment Group increased its stake in ResMed by 8.1% in the fourth quarter. Brooklyn Investment Group now owns 911 shares of the medical equipment provider's stock valued at $208,000 after acquiring an additional 68 shares during the period. Institutional investors and hedge funds own 54.98% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Stifel Nicolaus cut their price objective on ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a report on Wednesday, March 5th. JPMorgan Chase & Co. increased their price objective on shares of ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Morgan Stanley began coverage on shares of ResMed in a report on Wednesday, March 19th. They set an "overweight" rating and a $280.00 target price for the company. UBS Group upgraded ResMed from a "hold" rating to a "strong-buy" rating in a report on Friday, January 31st. Finally, Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, ResMed presently has a consensus rating of "Moderate Buy" and a consensus target price of $249.73.

Insiders Place Their Bets

In other news, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the sale, the chief executive officer now directly owns 455,472 shares in the company, valued at approximately $107,842,105.44. The trade was a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $227.71, for a total value of $455,420.00. Following the completion of the transaction, the director now directly owns 75,218 shares of the company's stock, valued at $17,127,890.78. This represents a 2.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,940 shares of company stock worth $9,164,385 in the last quarter. Corporate insiders own 0.71% of the company's stock.

ResMed Stock Performance

Shares of RMD traded down $1.59 during midday trading on Tuesday, reaching $222.26. The stock had a trading volume of 200,481 shares, compared to its average volume of 1,000,296. The firm has a market cap of $32.64 billion, a PE ratio of 26.22, a P/E/G ratio of 1.53 and a beta of 0.74. The firm has a 50 day simple moving average of $233.37 and a 200-day simple moving average of $237.83. ResMed Inc. has a one year low of $172.19 and a one year high of $263.05. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. As a group, sell-side analysts anticipate that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date was Thursday, February 13th. ResMed's dividend payout ratio is currently 25.03%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.